Archives of Gynecology and Obstetrics

, Volume 287, Issue 1, pp 161–166 | Cite as

Does obesity compromise ovarian reserve markers? A clinician’s perspective

  • Neena Malhotra
  • Anupama Bahadur
  • Neeta Singh
  • Mani Kalaivani
  • Suneeta Mittal
Reproductive Medicine



The aim of the study was to ascertain if increasing body mass index (BMI) adversely affects ovarian reserve among infertile women of Asian origin undergoing in vitro fertilization (IVF).

Materials and methods

This prospective study on 183 women was carried out in the infertility clinic of All India Institute of Medical Sciences, New Delhi, India. Blood hormonal assay in all patients including follicle-stimulating hormone (FSH), luteinizing hormone (LH) and inhibin B was performed on day 2/3 of a spontaneous cycle. A transvaginal ultrasonographic examination on day 2–5 of the menstrual cycle was done for antral follicle count (AFC) and ovarian volume. A correlation between BMI and ovarian reserve parameters like FSH, LH, inhibin B, antral follicle count and ovarian volume was noted.


Age was comparable in the three BMI groups. The mean duration of infertility was 8.38 years. Compared to the normal weight, the overweight and obese women had a statistically significantly low inhibin B (p < 0.0259). The AFC when taken together on both sides was not statistically significant between the groups; however, the overweight and obese women had a significantly low AFC (p < 0.0129) on the right side.


Incorporating anti-mullerian hormone, a newer marker for ovarian reserve, may benefit these obese infertile women. Further work is required to elucidate the mechanisms underlying the effect of obesity on inhibin B as a marker of ovarian reserve in infertile women. The best marker to check the ovarian reserve is perhaps the woman’s performance during an IVF cycle. However, considering the psychological and financial stress of the procedure, it may seem wise to consider counseling of obese women on their expected performance in the first cycle of IVF through such studies.


Obesity BMI Ovarian reserve 


  1. 1.
    Facts about overweight and obesity. Available from:
  2. 2.
    Haslam DW, James WP (2005) Obesity. Lancet 366:1197–1209PubMedCrossRefGoogle Scholar
  3. 3.
    Metwally M, Li TC, Ledger WL (2007) The impact of obesity on female reproductive function. Obes Rev 8:515–523PubMedCrossRefGoogle Scholar
  4. 4.
    Gil-Campos M, Canete RR, Gil A (2004) Adiponectin, the missing link in insulin resistance and obesity. Clin Nutr 23:963–974PubMedCrossRefGoogle Scholar
  5. 5.
    Spicer LJ (2001) Leptin A possible metabolic signal affecting reproduction. Domest Anim Endocrinol 21:251–270PubMedCrossRefGoogle Scholar
  6. 6.
    Brannian JD, Hansen KA (2002) Leptin and ovarian folliculogenesis: implications for ovulation induction and ART outcomes. Semin Reprod Med 20:103–112PubMedCrossRefGoogle Scholar
  7. 7.
    Moschos S, Chan JL, Mantzoros CS (2002) Leptin and reproduction: a review. Fertil Steril 77:433–444PubMedCrossRefGoogle Scholar
  8. 8.
    Clark AM, Ledger W, Galletly C, Tomlinson L, Blaney F, Wang X et al (1995) Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women. Hum Reprod 10:2705–2712PubMedCrossRefGoogle Scholar
  9. 9.
    Shah DK, Missmer SA, Berry KF, Racowsky C, Ginsburg ES (2011) Effect of obesity on oocyte and embryo quality in women undergoing in vitro fertilization. Obstet Gynecol 118(1):63–70PubMedCrossRefGoogle Scholar
  10. 10.
    Rittenberg V, Seshadri S, Sunkara SK, Sobaleva S, Oteng-Ntim E, El-Toukhy T (2011) Effect of body mass index on IVF treatment outcome: an updated systematic review and meta-analysis. Reprod Biomed Online 23(4):421–439PubMedCrossRefGoogle Scholar
  11. 11.
    Wu LL, Norman RJ, Robker RL (2011) The impact of obesity on oocytes: evidence for lipotoxicity mechanisms. Reprod Fertil Dev 24(1):29–34PubMedCrossRefGoogle Scholar
  12. 12.
    Poretsky L, Cataldo NA, Rosenwaks Z, Guidice LC (1999) The insulin-related ovarian regulatory system in health and disease. Endocr Rev 20:535–582PubMedCrossRefGoogle Scholar
  13. 13.
    Wang JX, Davies M, Norman RJ (2000) Body mass and probability of pregnancy during assisted reproduction treatment: retrospective study. BMJ 321:1320–1321PubMedCrossRefGoogle Scholar
  14. 14.
    Gonzalez F, Rote NS, Minium J, Kirwan JP (2006) Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome. J Clin Endocrinol Metab 91:336–340PubMedCrossRefGoogle Scholar
  15. 15.
    Agarwal A, Gupta S, Sharma RK (2005) Role of oxidative stress in female reproduction. Reprod Biol Endocrinol 3:28–49PubMedCrossRefGoogle Scholar
  16. 16.
    Broekmans FJ, Kwee J, Hendriks DJ, Mol BW, Lambalk CB (2006) A systematic review of tests predicting ovarian reserve and IVF outcome. Hum Reprod Update 12:685–718PubMedCrossRefGoogle Scholar
  17. 17.
    Klinkert ER, Broekmans FJ, Looman CW, Habbema JD, te Velde ER (2005) The antral follicle count is a better marker then basal follicle stimulating hormone for the selection of older patients with acceptable pregnancy prospects after in vitro fertilization. Fertil Steril 83:811–814PubMedCrossRefGoogle Scholar
  18. 18.
    Tinkanen H, Bläuer M, Laippala P, Tuohimaa P, Kujansuu E (2001) Correlation between serum Inhibin B and other indicators of the ovarian function. Eur J Obstet Gynecol Reprod Biol 94:109–113PubMedCrossRefGoogle Scholar
  19. 19.
    Franchimont P, Hazeé-Hagelstein MT, Charlet-Renard C, Jaspar JM, Hazout A, Salat-Baroux J et al (1990) Correlation between follicular fluid content and the results of in vitro fertilization and embryo transfer. II. Inhibin and aromatase inhibitor activity. J Clin Endocrinol Metab 71:748–754PubMedCrossRefGoogle Scholar
  20. 20.
    Fowler PA, Fahy U, Culler MD, Knight PG, Wardle PG, McLaughlin EA et al (1995) Gonadotrophin surge-attenuating factor bioactivity is present in follicular fluid from naturally cycling women. Hum Reprod 10:68–74PubMedCrossRefGoogle Scholar
  21. 21.
    De Pergola G, Maldera S, Tartagni M, Pannacciulli N, Loverro G, Giorgino R (2006) Inhibitory effect of obesity on gonadotropin, estradiol and Inhibin B levels in fertile women. Obesity 14(11):1954–1960PubMedCrossRefGoogle Scholar
  22. 22.
    Cortet-Rudelli C, Pigny P, Decanter C, Leroy M, Maunoury-Lefebvre C, Thomas-Desrousseaux P, Dewailly D (2002) Obesity and serum luteinizing hormone level have an independent and opposite effect on the serum inhibin B level in patients with polycystic ovary syndrome. Fertil Steril 77(2):281–287PubMedCrossRefGoogle Scholar
  23. 23.
    Popovic-Todorovic B, Loft A, Lindhard A, Bangsboll S, Andersson AM, Andersen AN (2003) A prospective study of predictive factors of ovarian response in ‘standard’ IVF/ICSI patients treated with recombinant FSH. A suggestion for a recombinant FSH dosage normogram. Hum Reprod 18:781–787PubMedCrossRefGoogle Scholar
  24. 24.
    Hotamisligil GS, Shargill NS, Spiegelman BM (1993) Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259:87–91PubMedCrossRefGoogle Scholar
  25. 25.
    Cancello R, Clément K (2006) Is obesity an inflammatory illness? Role of low-grade inflammation and macrophage infiltration in human white adipose tissue. Br J Obstet Gynaecol 113:1141–1147CrossRefGoogle Scholar
  26. 26.
    Cnattingius S, Bergstrom R, Cnattingius L, Kramer MS (1998) Prepregnancy weight and the risk of adverse pregnancy outcomes. N Engl J Med 338:147–152PubMedCrossRefGoogle Scholar
  27. 27.
    Kristensen J, Vestergaard M, Wisborg K, Kesmodel U, Secher NJ (2005) Pre-pregnancy weight and the risk of stillbirth and neonatal death. BJOG 112:403–408PubMedCrossRefGoogle Scholar
  28. 28.
    Nohr EA, Bech BH, Davies MJ, Frydenberg M, Henriksen TB, Olsen J (2005) Prepregnancy obesity and fetal death: a study within the Danish National Birth Cohort. Obstet Gynecol 106:250–259PubMedCrossRefGoogle Scholar
  29. 29.
    Balen AH, Dresner M, Scott EM, Drife JO (2006) Should obese women with polycystic ovary syndrome receive treatment for infertility? Br Med J 332:434–435 (Editorial)CrossRefGoogle Scholar
  30. 30.
    Nelson SM, Fleming RF (2007) The preconceptual contraception paradigm: markers of inflammation and placental function throughout obesity and infertility. Hum Reprod 22:912–915PubMedCrossRefGoogle Scholar
  31. 31.
    Seifer DB, Maclaughlin DT (2007) Mullerian inhibiting substance is an ovarian growth factor of emerging clinical significance. Fertil Steril 88:539–546PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Neena Malhotra
    • 1
  • Anupama Bahadur
    • 1
  • Neeta Singh
    • 1
  • Mani Kalaivani
    • 2
  • Suneeta Mittal
    • 1
    • 2
  1. 1.Departments of Obstetrics and GynecologyAll India Institute of Medical SciencesNew DelhiIndia
  2. 2.Department of BiostatisticsAll India Institute of Medical SciencesNew DelhiIndia

Personalised recommendations